REGN Stock Overview
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 1/6 |
Past Performance | 3/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for REGN from our risk checks.
Community Narratives
Narratives bring a range of perspectives from our community.
Innovative Therapies And Critical Market Expansions Fuel Biotech Growth
US$1.1k
FV
1.8% overvalued intrinsic discount7.63%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
12 days agoauthor updated this narrative
Regeneron Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1,082.19 |
52 Week High | US$1,115.00 |
52 Week Low | US$765.28 |
Beta | 0.13 |
11 Month Change | 4.64% |
3 Month Change | 12.89% |
1 Year Change | 41.20% |
33 Year Change | 77.16% |
5 Year Change | 254.94% |
Change since IPO | 5,022.79% |
Recent News & Updates
Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Aug 04Regeneron's Robust Pipeline And Financial Health Signal Continued Growth
Aug 02Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
Jul 11Recent updates
Risks To Shareholder Returns Are Elevated At These Prices For Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Aug 04Regeneron's Robust Pipeline And Financial Health Signal Continued Growth
Aug 02Regeneron: Downgrading My Outlook To 'Hold' Ahead Of Q2 Earnings
Jul 11Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) CEO Compensation Looks Acceptable To Us And Here's Why
Jun 08These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
May 21Regeneron: Dissecting The First Quarter Results And Regulatory Setbacks
May 06Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) Popularity With Investors Is Under Threat From Overpricing
Apr 30Is There An Opportunity With Regeneron Pharmaceuticals, Inc.'s (NASDAQ:REGN) 47% Undervaluation?
Apr 10Regeneron's Triple Threat: Eylea, Libtayo, And Dupixent Dominate
Mar 26Regeneron Pharmaceuticals' (NASDAQ:REGN) Conservative Accounting Might Explain Soft Earnings
Feb 16Regeneron Pharmaceuticals: Time To Change My Strategy After Encouraging Q4 2024
Feb 10Regeneron's Push Into Obesity, Q4 2023 Earnings Review
Feb 02These 4 Measures Indicate That Regeneron Pharmaceuticals (NASDAQ:REGN) Is Using Debt Reasonably Well
Jan 31Is Regeneron Pharmaceuticals (NASDAQ:REGN) A Risky Investment?
Oct 25Shareholder Returns
REGN | US Biotechs | US Market | |
---|---|---|---|
7D | 0.3% | -3.0% | -2.8% |
1Y | 41.2% | 15.5% | 16.6% |
Return vs Industry: REGN exceeded the US Biotechs industry which returned 15.5% over the past year.
Return vs Market: REGN exceeded the US Market which returned 16.6% over the past year.
Price Volatility
REGN volatility | |
---|---|
REGN Average Weekly Movement | 2.2% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 6.1% |
10% most volatile stocks in US Market | 14.5% |
10% least volatile stocks in US Market | 3.1% |
Stable Share Price: REGN has not had significant price volatility in the past 3 months.
Volatility Over Time: REGN's weekly volatility (2%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1988 | 13,926 | Leonard Schleifer | www.regeneron.com |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults.
Regeneron Pharmaceuticals, Inc. Fundamentals Summary
REGN fundamental statistics | |
---|---|
Market cap | US$116.81b |
Earnings (TTM) | US$4.32b |
Revenue (TTM) | US$13.49b |
27.0x
P/E Ratio8.7x
P/S RatioIs REGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
REGN income statement (TTM) | |
---|---|
Revenue | US$13.49b |
Cost of Revenue | US$6.30b |
Gross Profit | US$7.19b |
Other Expenses | US$2.86b |
Earnings | US$4.32b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | 40.04 |
Gross Margin | 53.27% |
Net Profit Margin | 32.04% |
Debt/Equity Ratio | 7.0% |
How did REGN perform over the long term?
See historical performance and comparison